Aprinoia Therapeutics (Aprinoia Therapeutics) Gross Margin % : 0.00% (As of Jun. 2023)

View and export this data going back to 2050. Start your Free Trial

What is Aprinoia Therapeutics Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Aprinoia Therapeutics's Gross Profit for the six months ended in Jun. 2023 was $9.03 Mil. Aprinoia Therapeutics's Revenue for the six months ended in Jun. 2023 was $9.03 Mil. Therefore, Aprinoia Therapeutics's Gross Margin % for the quarter that ended in Jun. 2023 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.

The historical rank and industry rank for Aprinoia Therapeutics's Gross Margin % or its related term are showing as below:

APRI's Gross Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: 59.4
* Ranked among companies with meaningful Gross Margin % only.

Aprinoia Therapeutics had a gross margin of N/A% for the quarter that ended in Jun. 2023 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Aprinoia Therapeutics was 0.00% per year.

Aprinoia Therapeutics Gross Margin % Historical Data

The historical data trend for Aprinoia Therapeutics's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aprinoia Therapeutics Gross Margin % Chart

Aprinoia Therapeutics Annual Data

Trend

Dec21

Dec22

Gross Margin %

Aprinoia Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23
Gross Margin %	-	-	-	-

Competitive Comparison of Aprinoia Therapeutics's Gross Margin %

For the Biotechnology subindustry, Aprinoia Therapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aprinoia Therapeutics's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aprinoia Therapeutics's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Aprinoia Therapeutics's Gross Margin % falls into.

Aprinoia Therapeutics Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Aprinoia Therapeutics's Gross Margin for the fiscal year that ended in Dec. 2022 is calculated as

Gross Margin % (A: Dec. 2022 )	=	Gross Profit (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	0.4	/	0.394
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(0.394 - 0)	/	0.394
	=	N/A %

Aprinoia Therapeutics's Gross Margin for the quarter that ended in Jun. 2023 is calculated as

Gross Margin % (Q: Jun. 2023 )	=	Gross Profit (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	9	/	9.034
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(9.034 - 0)	/	9.034
	=	N/A %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Aprinoia Therapeutics (NAS:APRI) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Aprinoia Therapeutics had a gross margin of N/A% for the quarter that ended in Jun. 2023 => No sustainable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

Aprinoia Therapeutics Gross Margin % Related Terms

Thank you for viewing the detailed overview of Aprinoia Therapeutics's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Aprinoia Therapeutics (Aprinoia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aprinoia Therapeutics Inc (NAS:APRI) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.

Aprinoia Therapeutics (Aprinoia Therapeutics) Headlines

No Headlines